pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,883 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1772Endpoints1378Fierce Biotech697BioSpace689BioPharma Dive522raps231onclive165fda recalls111
therapy area
allOncology12280Rare Disease3178Immunology2859Cardiology2719Hematology2154Pulmonology2135Vaccines
  • Endpoints News identifies 25 biopharma CEOs earning $25M or more in 2025
    Endpoints News released a ranking of the highest-paid chief executives in the biopharma sector for 2025. For the first time in four years the publication raised the minimum compensation threshold…
    Endpoints · 5mo agoNeutral↗ source
  • Biopharma pay series to return with new installments
    The publisher announced that new installments of its biopharma pay series will be released in the near future. The series traditionally examines compensation trends and salary data across the phar…
    Endpoints · 5mo agoNeutral↗ source
← prev
page 58 of 76
next →
fda medwatch109
globenewswire health73
fda press59
1787
Psychiatry & CNS1200
Ophthalmology1036
Endocrinology & Metabolism775
Pain768
Nephrology758
Nearly one in five patients stopped Boehringer's obesity shot in Phase 3 trial because of side effects
Boehringer Ingelheim’s obesity drug survodutide, licensed from Zealand Pharma, was evaluated in the Phase 3 SYNCHRONIZE-1 study. The trial reported that 19% of participants discontinued the treatm…
Endpoints · 5mo agoNegative readoutNegative↗ source
  • Pfizer's Berobenatide GLP-1 injection shows efficacy in obesity and diabetes in early data
    Pfizer presented early data on its long-acting GLP-1 injection, Berobenatide, at a conference on June 6, 2026. The results indicated the drug was effective in patients who have both obesity and d…
    Endpoints · 5mo agoPositive readoutPositive↗ source
  • Roche to launch Phase 2 trial of petrelintide and enicepatide combination for obesity
    Roche announced it will begin a Phase 2 study this year testing a combination of its two obesity candidates, petrelintide and enicepatide. The company describes petrelintide as having a potentiall…
    Endpoints · 5mo agoCRLPositive↗ source
  • Lawmakers propose China restrictions and ASCO 2026 highlights
    The latest Endpoints Weekly notes that U.S. lawmakers are introducing new measures aimed at limiting certain activities with China, though details were not disclosed in the brief. The issue also r…
    Endpoints · 5mo agoNeutral↗ source
  • Roche's daily incretin injection shows promise in Phase 2 trial for type 1 diabetes
    Roche reported that its experimental daily incretin injection achieved positive results in a Phase 2 study involving patients with type 1 diabetes. The study, the first mid-stage trial of a GLP-1…
    Endpoints · 5mo agoPositive readoutPositive↗ source
  • Innovent Biologics reports Phase 3 success for stomach cancer ADC, now under priority review in China
    Innovent Biologics announced that its antibody‑drug conjugate (ADC) candidate has met the primary endpoint in a Phase 3 trial for advanced stomach cancer. The positive outcome has placed the produ…
    Endpoints · 5mo agoPositive readoutPositive↗ source
  • Fulcrum Therapeutics cuts workforce, retaining only nine employees as layoffs hit 48 staff
    Fulcrum Therapeutics announced a dramatic reduction in its staff, letting go of 48 of its 57 full‑time employees. The move leaves the company with just nine remaining workers, effectively turning i…
    Endpoints · 5mo agoLayoffsNegative↗ source
  • Biotech lobby groups in Washington push to keep Chinese low-cost drug pipeline open amid rising anti-China proposals
    Washington biotech lobby groups are working to ensure a steady flow of affordable medicines that originate from Chinese manufacturers. These groups have become aware that they are encountering voc…
    Endpoints · 5mo agoRegulatoryNeutral↗ source
  • Industry and rare disease groups call for more transparency in FDA voucher pilot
    The pharmaceutical industry and rare‑disease advocacy groups have voiced concerns about the Commissioner's National Priority Voucher pilot program. Stakeholders say the program lacks transparency…
    Endpoints · 5mo agoRegulatoryNegative↗ source
  • House Appropriations Committee urges FDA to accelerate IND approvals for clinical trials
    The House Appropriations Committee issued a directive to the Food and Drug Administration, calling for reforms to speed up the Investigational New Drug (IND) sign-off process for new clinical trial…
    Endpoints · 5mo agoRegulatoryNeutral↗ source
  • Uli Stilz joins Flagship while Revolution Medicines adds Alex Hoffman as commercial lead
    On June 5, 2026, biotech veteran Uli Stilz announced his new position at Flagship, marking a notable personnel shift in the industry. Stilz has spent much of the year traveling internationally, in…
    Endpoints · 5mo agoNeutral↗ source
  • Novo Nordisk Indiana plant faces FDA re-inspection after hair found in drugs and roof leaks threaten sterility
    Novo Nordisk's fill‑finish facility in Bloomington, Indiana underwent a follow‑up FDA inspection in April. The agency reported mammalian hair in finished drug containers and identified water leaks…
    Endpoints · 5mo agoRegulatoryNegative↗ source
  • Otsuka presents new data to bolster full approval bid for Voyxact in IgA nephropathy
    Otsuka Pharmaceutical announced that new clinical evidence has been generated for its monoclonal antibody Voyxact, aimed at treating IgA nephropathy, a chronic autoimmune kidney disease. The data,…
    Endpoints · 5mo agoRegulatoryPositive↗ source
  • Dimension Capital targets up to $750M for third life-sciences fund after strong portfolio performance
    Dimension Capital, a New York and San Francisco-based investment firm that blends machine learning with life-science ventures, announced it is launching its third fund. The firm is seeking up to $…
    Endpoints · 5mo agoDealPositive↗ source
  • FDA reinspects Novo Nordisk's Indiana plant, finds mammalian hair and roof leaks compromising drug sterility
    Novo Nordisk's manufacturing facility in Indiana, acquired from Catalent, has undergone a second FDA reinspection after earlier concerns. The April inspection revealed mammalian hair in finished d…
    Endpoints · 5mo agoRegulatoryNegative↗ source
  • Hikma invests $267 million in Ohio as Cingulate receives CRL for ADHD candidate
    Hikma Pharmaceuticals, a generic drugmaker, announced a $267 million investment to expand its manufacturing footprint in Ohio. The plan includes $216 million to upgrade its existing Columbus plant…
    Endpoints · 5mo agoDealNeutral↗ source
  • Novo Holdings invests €500 million in Europe-focused fund as Alnylam advances second obesity drug to clinic
    Novo Holdings, the investment arm of the Novo Nordisk Foundation, has committed €500 million to the Scaleup Europe Fund, a vehicle aimed at supporting European biotech scale‑ups. Alnylam Pharmaceu…
    Endpoints · 5mo agoDealPositive↗ source
  • Lilly and Boehringer cut German investments amid health-spending overhaul
    A proposed overhaul of Germany's health-insurance financing is sparking criticism from industry groups. Eli Lilly and Boehringer Ingelheim announced they will reduce their investment programmes in…
    Endpoints · 5mo agoRegulatoryNegative↗ source
  • Supreme Court unanimously backs Hikma's skinny label fish oil generic
    The U.S. Supreme Court issued a unanimous decision favoring Hikma Pharmaceuticals in a dispute over its skinny label version of a prescription-strength fish oil product. The court ruled that Hikma…
    Endpoints · 5mo agoRegulatoryPositive↗ source
  • Parabilis Medicines targets over $400 million in Nasdaq IPO to fund peptide pipeline
    Parabilis Medicines, a peptide-focused biotech led by former Johnson & Johnson R&D head Mathai Mammen, announced plans for a Nasdaq initial public offering. The company aims to raise more than $40…
    Endpoints · 5mo agoDealPositive↗ source
  • ADC Therapeutics' Zynlonta confirmatory trial shows higher death rates, clouding full approval prospects
    ADC Therapeutics is pursuing full FDA approval for its antibody-drug conjugate Zynlonta in patients with relapsed or refractory diffuse large B-cell lymphoma. In the confirmatory study presented,…
    Endpoints · 5mo agoRegulatoryNegative↗ source
  • ADC biotech Ona Therapeutics raises $86.6M in Series B to move two ADC candidates toward clinic
    Barcelona-based Ona Therapeutics announced a $86.6 million Series B financing round. The capital will be used to move two antibody‑drug conjugate (ADC) programs into early‑stage clinical testing.…
    Endpoints · 5mo agoDealPositive↗ source
  • Acting FDA Commissioner Kyle Diamantas says he will not seek permanent appointment
    Acting FDA Commissioner Kyle Diamantas has indicated that he does not intend to remain in the role on a permanent basis. Sources close to the administration say that the search for a new permanent…
    Endpoints · 5mo agoRegulatoryNeutral↗ source